Universitätsklinikum Tübingen

Quality assurance guidelines for superficial hyperthermia clinical trials: I. Clinical requirements (2017) Trefna HD, Crezee H, Schmidt M, Marder D, Lamprecht U, Ehmann M, Hartmann J, et al. Journal article Prognostic factors and outcomes in metastatic uveal melanoma treated with PD-1 or combined PD-1 / CTLA-4 inhibition (2017) Heppt M, Heinzerling L, Kaehler K, Forschner A, Kirchberger M, Loquai C, Meissner M, et al. Conference contribution Interleukin-2 and Checkpoint Inhibition as a successful Therapy Sequence for metastatic Melanoma: Case Report and retrospective Analysis in 52 Patients (2017) Cosgarea , Zimmer L, Weide B, Gutzmer R, Heinzerling L, Weishaupt C, Pfoehler C, et al. Conference contribution ARHGEF9 disease: Phenotype clarification and genotype-phenotype correlation (2017) Alber M, Kalscheuer VM, Marco E, Sherr E, Lesca G, Till M, Gradek G, et al. Journal article Rare Variant of GM2 Gangliosidosis through Activator-Protein Deficiency (2017) Brackmann F, Kehrer C, Kustermann W, Boehringer J, Kraegeloh-Mann I, Trollmann R Journal article Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer (2017) Goode EL, Block MS, Kalli KR, Vierkant RA, Chen W, Fogarty ZC, Gentry-Maharaj A, et al. Journal article Clinical characteristics and outcome of 60 pediatric patients with malignant melanoma registered with the German Pediatric Rare Tumor Registry (STEP) (2017) Offenmüller S, Leiter U, Bernbeck B, Garbe C, Eigentler T, Borkhardt A, Classen CF, et al. Journal article Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions (2017) Hassel JC, Heinzerling L, Aberle J, Baehr O, Eigentler TK, Grimm MO, Gruenwald V, et al. Journal article Quality assurance guidelines for superficial hyperthermia clinical trials : II. Technical requirements for heating devices (2017) Trefna HD, Crezee J, Schmidt M, Marder D, Lamprecht U, Ehmann M, Nadobny J, et al. Journal article Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma (2017) Zimmer L, Apuri S, Eroglu Z, Kottschade LA, Forschner A, Gutzmer R, Schlaak M, et al. Journal article